RxDoctor Payments Data

Delbert Kwan, MD

Urology · Lewes, DENPI 1619970258

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $545 of the $688 with a category attached, or 79.3%. 16 manufacturers reported payments, led by Boston Scientific at 26.8% of the total. 2025 is the largest year on record at $393, 4.8 times the $82 reported in 2019. That places this record below the midpoint for urology clinicians in DE, where the typical reported total is $2,396.

$688in general payments, 2019–2025

Across 27 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$184
  • Astellas Pharma US Inc$88
  • Teleflex LLC$59
  • Ferring Pharmaceuticals Inc.$44
  • AbbVie$39
  • AstraZeneca$35
  • plus $239 from 10 others

What the payments were for

  • Food & beverage$54579%
  • Education$14321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$688 in reported general payments places this provider in the 20th percentile of 33 urology providers in Delaware.

See all urology providers in Delaware

Medicare billing

Part B allowed, 2024
$521,026
Medicare patients
1,633
Services billed
10,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron120$113,716
GemtesaVibegron34$33,997
Tamsulosin Hcl1,260$24,387
Testosterone84$14,780
Finasteride790$14,477
Fesoterodine Fumarate ErFesoterodine Fumarate77$9,994
Potassium Citrate ErPotassium Citrate73$7,420
Silodosin38$6,716
Tadalafil16$3,238
Oxybutynin Chloride ErOxybutynin Chloride88$2,853
Solifenacin Succinate61$2,601
Alfuzosin Hcl ErAlfuzosin Hcl69$2,007
Dutasteride46$1,919
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim711$1,343
Allopurinol69$832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$88$113,716120 claims
Sumitomo Pharma America, Inc.Gemtesa$28$33,99734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 33 urology providers in Delaware.

Other urology in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →